Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revaccination with Pneumovax 23 in Older Japanese Adults
NCT02260882Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2014
- Primary completion
- Apr 2015
- Modality
- Split/Subunit Vaccines
01
Overview
A Phase 4 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Oct 2014; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02260882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260882.